• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others.

作者信息

Kantarci Mecit, Pirimoglu Berhan

机构信息

Department of Radiology, Faculty of Medicine, Ataturk University, 25040, Erzurum, Turkey.

出版信息

J Gastrointest Cancer. 2017 Sep;48(3):282-285. doi: 10.1007/s12029-017-9969-y.

DOI:10.1007/s12029-017-9969-y
PMID:28624974
Abstract
摘要

相似文献

1
Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others.肝细胞癌局部区域治疗的放射学反应：RECIST、mRECIST及其他
J Gastrointest Cancer. 2017 Sep;48(3):282-285. doi: 10.1007/s12029-017-9969-y.
2
Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.评估 HCC 对局部区域治疗的反应：基于 MRI 的反应标准与离体病理的验证。
J Hepatol. 2017 Dec;67(6):1213-1221. doi: 10.1016/j.jhep.2017.07.030. Epub 2017 Aug 18.
3
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.mRECIST 预测晚期肝细胞癌的生存：比较尼达尼布与索拉非尼的两项随机 II 期试验分析。
Liver Int. 2017 Jul;37(7):1047-1055. doi: 10.1111/liv.13359. Epub 2017 Feb 2.
4
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.索拉非尼治疗肝细胞癌患者的实体瘤反应评价标准（RECIST）和改良 RECIST 肿瘤反应比较。
Cancer. 2012 Jan 1;118(1):147-56. doi: 10.1002/cncr.26255. Epub 2011 Jun 28.
5
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.评价 mRECIST 和甲胎蛋白比值在索拉非尼治疗的晚期肝细胞癌患者预后分层中的作用。
Oncology. 2012;83(4):192-200. doi: 10.1159/000341347. Epub 2012 Aug 11.
6
EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.EASL 和 mRECIST 应答是接受冷冻消融治疗的肝细胞癌患者生存的独立预测因素。
Eur J Gastroenterol Hepatol. 2013 May;25(5):620-7. doi: 10.1097/MEG.0b013e32835ced13.
7
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.EASL 和 mRECIST 评价索拉非尼联合经动脉化疗栓塞治疗肝细胞癌的疗效反应可预测患者的生存。
Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.
8
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.索拉非尼治疗晚期肝细胞癌患者的CT成像结果：替代反应标准（Choi标准、欧洲肝脏研究协会标准以及改良实体瘤疗效评价标准（mRECIST））与RECIST 1.1标准的对比
Eur J Radiol. 2016 Jan;85(1):103-112. doi: 10.1016/j.ejrad.2015.10.024. Epub 2015 Nov 5.
9
Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.RECIST和mRECIST标准作为中期肝细胞癌患者接受重复碘油化疗栓塞术预后因素的疗效
Acta Radiol. 2015 Dec;56(12):1437-45. doi: 10.1177/0284185114560937. Epub 2014 Dec 5.
10
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.EASL 和 mRECIST 应答是经动脉栓塞治疗肝细胞癌患者生存的独立预后因素。
J Hepatol. 2011 Dec;55(6):1309-16. doi: 10.1016/j.jhep.2011.03.007. Epub 2011 Apr 15.

引用本文的文献

1
Assessment of the response to systemic treatment of colorectal liver metastases on cross-sectional imaging - a systematic review.基于横断面成像评估结直肠癌肝转移全身治疗的疗效——一项系统评价
Pol J Radiol. 2023 Nov 8;88:e512. doi: 10.5114/pjr.2023.132884. eCollection 2023.
2
Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC.CT纹理参数在肝癌患者疗效评估及生存预测中对肝癌治疗前后变化的研究
Front Oncol. 2022 Oct 28;12:957737. doi: 10.3389/fonc.2022.957737. eCollection 2022.
3
Objective response rate assessment in oncology: Current situation and future expectations.

本文引用的文献

1
How Can New Imaging Modalities Help in the Practice of Radiology?新的成像方式如何助力放射学实践？
Eurasian J Med. 2016 Oct;48(3):213-221. doi: 10.5152/eajm.2016.0260.
2
Non-Gaussian diffusion alterations on diffusion kurtosis imaging in patients with early Alzheimer's disease.早期阿尔茨海默病患者扩散峰度成像中的非高斯扩散改变
Neurosci Lett. 2016 Mar 11;616:11-8. doi: 10.1016/j.neulet.2016.01.021. Epub 2016 Jan 18.
3
PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response.肝脏钇-90微球沉积的PET/MRI可确定个体肿瘤反应。
肿瘤学中的客观缓解率评估：现状与未来期望。
World J Clin Oncol. 2020 Feb 24;11(2):53-73. doi: 10.5306/wjco.v11.i2.53.
4
Implications of Immunotherapy in Hepatobiliary Tumors.免疫疗法在肝胆肿瘤中的应用
Visc Med. 2019 Mar;35(1):18-26. doi: 10.1159/000496755. Epub 2019 Feb 8.
5
Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone.经动脉化疗栓塞术后伴有局部残留的大肝细胞癌：索拉非尼联合射频消融或单纯索拉非尼治疗
Am J Cancer Res. 2019 Apr 1;9(4):791-799. eCollection 2019.
Cardiovasc Intervent Radiol. 2016 Jun;39(6):855-64. doi: 10.1007/s00270-015-1285-y. Epub 2015 Dec 31.
4
Clinical Imaging of Tumor Metabolism with ¹H Magnetic Resonance Spectroscopy.¹H磁共振波谱在肿瘤代谢的临床成像
Magn Reson Imaging Clin N Am. 2016 Feb;24(1):57-86. doi: 10.1016/j.mric.2015.09.002.
5
Diffusion kurtosis imaging can efficiently assess the glioma grade and cellular proliferation.扩散峰度成像能够有效地评估胶质瘤的分级和细胞增殖情况。
Oncotarget. 2015 Dec 8;6(39):42380-93. doi: 10.18632/oncotarget.5675.
6
Diffusion kurtosis imaging to assess response to treatment in hypervascular hepatocellular carcinoma.扩散峰度成像评估富血管型肝细胞癌的治疗反应。
AJR Am J Roentgenol. 2015 May;204(5):W543-9. doi: 10.2214/AJR.14.13235.
7
Abdominal perfusion computed tomography.腹部灌注计算机断层扫描
Eurasian J Med. 2013 Feb;45(1):50-7. doi: 10.5152/eajm.2013.09.
8
Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: a preliminary result.使用体素内不相干运动（IVIM）磁共振成像预测经动脉化疗栓塞术后肝细胞癌患者的碘油摄取：初步结果。
Magn Reson Imaging. 2014 Jul;32(6):638-46. doi: 10.1016/j.mri.2014.03.003. Epub 2014 Mar 15.
9
Characterizing focal hepatic lesions by free-breathing intravoxel incoherent motion MRI at 3.0 T.在3.0T场强下通过自由呼吸体素内不相干运动磁共振成像对肝脏局灶性病变进行特征性分析。
Acta Radiol. 2014 Dec;55(10):1166-73. doi: 10.1177/0284185113514966. Epub 2013 Dec 6.
10
Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging.评价磁共振灌注成像引导下经导管肝动脉化疗栓塞治疗肝细胞癌的疗效。
Eur J Gastroenterol Hepatol. 2014 Jan;26(1):109-13. doi: 10.1097/MEG.0b013e328363716e.